PetVivo Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PetVivo Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Mar 31, 2017 | $7.1K | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | $75.0K | Nov 14, 2018 |
| FY2011 | Mar 31, 2012 | $0 | Jul 17, 2012 |
| FY2011 | Mar 31, 2011 | $0 | Jul 17, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.13M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $968.7K | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $917.2K | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $115.6K | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $12.6K | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | $3.6K | Jun 29, 2021 |
| FY2019 | Mar 31, 2018 | $1.5K | Jul 31, 2019 |
| FY2018 | Mar 31, 2017 | $7.1K | Aug 13, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $994.9K | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $866.9K | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $696.1K | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($85.6K) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $1.9K | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | ($16.1K) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($77.9K) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $1.5K | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | $7.1K | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | $75.0K | Nov 14, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($8.40M) | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | ($10.96M) | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | ($8.72M) | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($5.01M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($3.52M) | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | ($2.08M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($4.76M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($2.34M) | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | ($16.52M) | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | ($4.73M) | Nov 14, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($8.06M) | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | ($10.62M) | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | ($8.73M) | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($5.06M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($1.96M) | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | ($2.02M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($4.67M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($2.29M) | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | ($16.39M) | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | ($3.25M) | Nov 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.58M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $1.40M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $996.4K | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $474.9K | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $98.2K | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | $12.7K | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $201.0K | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $118.9K | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | $167.9K | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | $168.6K | Nov 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($5.32M) | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | ($7.42M) | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | ($6.79M) | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($4.17M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($767.2K) | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | ($498.1K) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($736.4K) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($575.2K) | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | ($143.0K) | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | ($690.3K) | Nov 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $63.4K | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $309.1K | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $423.9K | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $154.0K | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $140.7K | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | $32.8K | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $27.1K | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $19.2K | Jul 31, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $9.34M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $3.12M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $2.44M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $7.43M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $835.2K | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | $522.5K | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $691.1K | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $1.57M | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | $1.90M | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | $16.69M | Nov 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.12M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $2.43M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | $1.71M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $1.44M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $1.73M | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | $1.56M | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $1.54M | Jun 29, 2020 |
| FY2014 | Mar 31, 2014 | $479.1K | Jul 14, 2014 |
| FY2012 | Mar 31, 2013 | $256.5K | Jul 17, 2013 |
| FY2012 | Mar 31, 2012 | $179.0K | Jul 17, 2013 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.22M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | $686.0K | Jul 10, 2025 |
| FY2025 | Mar 31, 2023 | $725.0K | Jul 10, 2025 |
| FY2024 | Mar 31, 2022 | $5.99M | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | ($897.0K) | Jun 29, 2023 |
| FY2022 | Mar 31, 2020 | ($1.04M) | Jun 24, 2022 |
| FY2021 | Mar 31, 2019 | ($844.8K) | Jun 29, 2021 |
| FY2020 | Mar 31, 2018 | $136.6K | Jun 29, 2020 |
| FY2019 | Mar 31, 2017 | $819.7K | Jul 31, 2019 |
| FY2017 | Mar 31, 2016 | ($70.3K) | Nov 14, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Mar 31, 2019 | $13.41M | Jul 31, 2019 |
| FY2018 | Mar 31, 2018 | $13.41M | Aug 13, 2018 |
| FY2017 | Mar 31, 2016 | $13.41M | Nov 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($91.20M) | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | ($82.80M) | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | ($71.84M) | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($63.13M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($58.11M) | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | ($54.59M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($52.51M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($47.75M) | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | ($45.41M) | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | ($29.88M) | Nov 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $87.4K | Jun 28, 2024 |
| FY2024 | Mar 31, 2023 | $475.3K | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $6.11M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $23.6K | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | $888 | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $6.5K | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $237.3K | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | $25.4K | Nov 14, 2018 |
| FY2017 | Mar 31, 2016 | $258 | Nov 14, 2018 |
| FY2017 | Mar 31, 2015 | $39.9K | Nov 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Jun 24, 2022 |
| FY2011 | Mar 31, 2012 | 0 | Jul 17, 2012 |
| FY2011 | Mar 31, 2011 | 0 | Jul 17, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jun 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 24.18M | Jul 10, 2025 |
| FY2025 | Mar 31, 2024 | 17.06M | Jul 10, 2025 |
| FY2024 | Mar 31, 2023 | 10.95M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | 9.99M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 6.80M | Jun 24, 2022 |
| FY2021 | Mar 31, 2020 | 5.73M | Jun 29, 2021 |
| FY2020 | Nov 30, 2019 | 22.48M | Jun 29, 2020 |
| FY2020 | Mar 31, 2019 | 19.87M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | 18.28M | Jul 31, 2019 |
| FY2017 | Mar 31, 2017 | 9.32M | Nov 14, 2018 |